EBOS Announces Successful Placement

Not for release to US wire services or distribution in the United States

10 December 2021
NZX / ASX Code: EBO
EBOS ANNOUNCES SUCCESSFUL COMPLETION OF NZ$674 MILLION
PLACEMENT
EBOS Group Limited (“EBOS”) is pleased to announce the successful completion of the fully
underwritten placement ("Placement") of approximately 19.5 million new fully paid ordinary shares
(“New Shares”), raising approximately NZ$674 million / A$642 million
1
to partly fund the acquisition
of LifeHealthcare.
The issue price of NZ$34.50 represented a 5.5% discount to the closing price on NZX of NZ$36.50 per
share, as at 8 December 2021. The Placement was strongly supported by a broad range of existing
and new investors across New Zealand, Australia and offshore. Eligible shareholders who bid for an
amount less than or equal to their ‘pro rata’ share
2
of New Shares under the Placement and Retail
Offer have been allocated their full bid on a best endeavours basis.
John Cullity, EBOS Chief Executive Officer, said: “We are very encouraged by the strong support from
investors for the Placement and in particular, the level of support from our existing shareholders.
We are also pleased to have the opportunity to welcome new high-quality investors to the register.
The acquisition of LifeHealthcare accelerates EBOS’ medical devices strategy and creates a platform
for EBOS to capitalise on additional future growth opportunities. We look forward to completion and
the integration of LifeHealthcare into our existing institutional healthcare division.”
EBOS Chair, Liz Coutts added, “It is very pleasing to see the support EBOS has received for this
transaction. I encourage our retail shareholders in New Zealand and Australia to read and consider
the retail offer booklet that will be distributed to you in the coming days. We look forward to
continuing to drive future growth through our disciplined investment strategy to create further
shareholder value.”
EBOS’ ordinary shares will recommence trading upon market open today. Settlement of the
Placement is expected to occur on Tuesday, 14 December and Wednesday, 15 December for the ASX
and NZX respectively, with allotment of all New Shares (representing approximately 11.9% of EBOS’
existing shares on issue) on Wednesday, 15 December. The New Shares issued under the Placement
will rank equally with EBOS existing ordinary shares on issue.


1
Assumes an AUD NZD exchange rate of 1.0499 as at 8 December 2021.
2
For this purpose, an eligible institutional shareholder’s ‘pro rata’ share of New Shares under the Placement and Retail Offer (based on
the NZ$674 million target size) will be estimated by reference to EBOS’ beneficial register on 24 November 2021, but without undertaking
any reconciliation processes. Unlike in a rights issue, this may not truly reflect the participating shareholder’s actual pro rata share of the
New Shares under the Placement and Retail Offer. Nothing in this release gives a shareholder a right or entitlement to participate in the
Placement or Retail Offer and EBOS has no obligation to reconcile assumed holdings (e.g. for recent trading or swap positions) when
determining a shareholder’s ‘pro rata’ share of New Shares under the Placement and Retail Offer. Investors who do not reside in New
Zealand or Australia or other eligible jurisdictions will not be able to participate in the Placement. EBOS and the Lead Manager disclaim
any duty or liability (including for negligence) in respect of the determination of a shareholder’s ‘pro rata’ share of New Shares under the
Placement and the Retail Offer.

RETAIL OFFER
As previously announced, EBOS intends to conduct a non-underwritten retail offer to eligible existing
shareholders to raise up to NZ$105 million (A$100 million
3
), with the ability to accept
oversubscriptions at EBOS’ discretion (Retail Offer).
Full details of the Retail Offer will be set out in the Retail Offer Booklet, which will be released to the
NZX and ASX, and sent to eligible shareholders on or about Wednesday, 15 December 2021. The
closing date for applications by eligible shareholders is Monday, 17 January 2022.
KEY DATES
Description Date
Record date (for identifying shareholders eligible to
participate in the Retail Offer)
7pm (NZDT) Wednesday, 8
December 2021
ASX settlement of New Shares issued under the Placement Tuesday, 14 December 2021
NZX settlement of New Shares issued under the Placement Wednesday, 15 December 2021
ASX and NZX allotment and normal trading of New Shares
issued under the Placement
Wednesday, 15 December 2021
Retail Offer opens and Retail Offer Booklet is dispatched Wednesday, 15 December 2021
Retail Offer closes Monday, 17 January 2022
Retail Offer Issue Price announced Tuesday, 18 January 2022
Retail Offer allotment date Monday, 24 January 2022
Commencement of normal trading of new shares issued under
the Retail Offer on NZX Main Board
Monday, 24 January 2022
Commencement of normal trading of new shares issued under
the Retail Offer on ASX
Tuesday, 25 January 2022
Despatch of holding statements Friday, 28 January 2022

This release was authorised for lodgement with NZX and ASX by the Chief Executive Officer.

For further information, please contact:
Investor Relations:

Martin Krauskopf
General Manager, M&A and Investor Relations
EBOS Group
martin.krauskopf@ebosgroup.com


3
Assumes an AUD NZD exchange rate of 1.0499 as at 8 December 2021.

Media:

New Zealand:
Geoff Senescall
Senescall Akers
+64 21 481 234

Australia:
Patrick Rasmussen
PRX
+61 430 159 690

ABOUT EBOS GROUP
EBOS Group Limited NZBN 9429031998840 (NZX/ASX Code: EBO) is the largest and most diversified
Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical
products. It is also a leading Australasian animal care brand owner, product marketer and
distributor.

NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES
This market release has been prepared for publication in Australia and New Zealand and may not be
released to US wires services or distributed in the United States. This market release does not
constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or
any other jurisdiction. The securities referred to in this release have not been, and will not be,
registered under the US Securities Act of 1933 or the securities laws of any state or other jurisdiction
of the United States and, as a result, the securities may not be offered, sold or resold, directly or
indirectly, in the United States or to persons acting for the account or benefit of a person in the
United States (to the extent such persons hold EBOS shares and are acting for the account or benefit
of a person in the United States) except in transactions exempt from, or not subject to, the
registration requirements of the US Securities Act and the applicable securities laws of any state or
other jurisdiction of the United States.
You must not send copies of this announcement or any other material relating to the Retail Offer to
any person in the United States or elsewhere outside Australia and New Zealand.
FORWARD LOOKING STATEMENTS
This market release contains forward looking statements which are identified by words such as
‘may’, ‘could’, ‘believes’, ‘estimates’, ‘expects’, ‘intends’ and other similar expressions that are
intended to identify forward-looking statements. Indications of, and guidance on, future earnings
and financial position and performance are also forward-looking statements.
Forward-looking statements, opinions and estimates provided in this announcement are based on
assumptions and contingencies that are subject to change without notice and involve known and

unknown risks, uncertainties, assumptions, contingencies and other factors, many of which are
beyond the control of EBOS and its related bodies corporate and affiliates and each of their
respective directors, securityholders, officers, employees, partners, agents, advisers and
management. This includes statements about market and industry trends, which are based on
interpretations of market conditions.
Investors are strongly cautioned not to place undue reliance on forward-looking statements,
particularly in light of the current economic climate and the significant volatility, uncertainty and
disruption caused by the Covid pandemic. Forward-looking statements are provided as a general
guide only and should not be relied on as an indication or guarantee of future performance. Actual
results, performance or achievements may differ materially from those expressed or implied in
those statements and any projections and assumptions on which these statements are based.
These statements may assume the success of EBOS’ business strategies, the success of which may
not be realised within the period for which the forward-looking statements may have been
prepared, or at all.
No guarantee, representation or warranty, express or implied, is made as to the accuracy, likelihood
of achievement or reasonableness of any forecasts, prospects, returns, statements or tax treatment
in relation to future matters contained in this announcement.
These forward-looking statements speak only as of the date of this market release, and except as
required by applicable laws or regulations, EBOS, its representatives or advisers do not undertake to
publicly update or revise any forward- looking statement or other statements in this announcement,
whether as a result of a change in expectations or assumptions, new information, future events,
results or circumstances. Past performance and pro forma historical financial information is given for
illustrative purposes only. It should not be relied on and it is not indicative of future performance,
including future security prices.
IMPORTANT NOTICE
This market release does not constitute investment or financial product advice, nor is it a
recommendation to acquire shares in EBOS. It is not intended to be used as the basis for making a
financial decision, nor is it intended to constitute legal, tax, accounting or other advice. You should
make your own enquiries and investigations regarding any investment, and should seek your own
professional advice on the legal, financial, accounting, taxation and other consequences of investing
in EBOS.
This market release is not a prospectus, product disclosure statement or any other disclosure or
offering document under New Zealand and Australian law (and has not been, and will not be, lodged
with the Australian Securities and Investments Commission) or any other law. This market release is
for information purposes only and is not an invitation or offer of securities for subscription, purchase
or sale in any jurisdiction and neither this market release nor anything in it shall form any part of any
contract for the acquisition of EBOS shares.